Shares of Incyte Corporation (NASDAQ:INCY) rose 3.6% on Thursday after the biopharmaceutical firm named Bill Meury as its new President and Chief Executive Officer, effective immediately.
Meury, a seasoned executive with more than 30 years in the pharmaceutical industry, takes over from Hervé Hoppenot, who is retiring after over a decade at the company’s helm. Hoppenot will remain onboard through the end of 2025 as an advisor and board member to support a seamless leadership transition.
Meury’s track record includes recent leadership roles at Anthos Therapeutics, which was acquired by Novartis (NYSE:NVS) in April 2025, and Karuna Therapeutics (NASDAQ:KRTX), which merged with Bristol Myers Squibb (NYSE:BMY) in early 2024. He also spent more than two decades at Allergan (NYSE:AGN), ultimately serving as Chief Commercial Officer, overseeing a global portfolio of 50 products that generated $16 billion in annual sales.
In a statement, Meury emphasized his commitment to advancing Incyte’s product pipeline and long-term value creation. “My focus will be on leveraging our strong R&D and commercial foundation to accelerate innovation, drive consistent growth, and deliver value across all stakeholders,” he said.
As part of the leadership reshuffle, Julian Baker, previously Lead Independent Director, has been appointed as Chairman of the Board.
The market reacted positively to the announcement, signaling investor confidence in Meury’s experience and strategic vision for Incyte’s next chapter.